Chin Richard 4

What Happened
Richard Chin, a director of Cytek Biosciences (CTKB), had restricted stock units (RSUs) convert to 6,107 shares on May 18, 2026 (reported on a Form 4 filed May 20, 2026). The filing shows an acquisition/conversion of 6,107 shares (derivative conversion) and a simultaneous disposition of 6,107 shares for $0.00. The zero-dollar disposition is consistent with shares being surrendered rather than a cash sale (commonly to satisfy tax-withholding obligations).

Key Details

• Transaction date: May 18, 2026; Form 4 filed May 20, 2026 (within the 2‑business‑day reporting window).
• Acquired: 6,107 shares via conversion of RSUs (transaction code M).
• Disposed: 6,107 shares at $0.00 (derivative disposal; no cash proceeds reported).
• Footnotes: F1 = each RSU converts to one share; F2 = vesting schedule shows a portion (3/36) of the award vested on May 18, 2026.
• Shares owned after the reported transactions are not specified in the filing.

Context
This was not an open‑market buy or sale but a routine conversion/vesting of RSUs into stock with an equal number of shares surrendered (typically for tax withholding). Such derivative conversions reflect compensation vesting rather than a directional market bet by the insider.